Loading...
Anti-programmed cell death-1/ligand-1 (PD-1/PD-L1) antibodies for the treatment of urothelial carcinoma: state-of-the-art and future development
INTRODUCTION/BACKGROUND: Immunotherapy with programmed cell death-1/ligand-1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those w...
Na minha lista:
| Udgivet i: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5878995/ https://ncbi.nlm.nih.gov/pubmed/29325739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.11.002 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|